Aims: Sarcopenia and physical disability assessed by a 6-min walking test (6MWT) are associated with poor prognosis of patients with chronic liver disease (CLD). However, CLD patients with hepatocellular carcinoma (HCC) mostly rest in bed during hospitalization. We aimed to investigate the effects of therapeutic exercise on liver function, 6MWT, and skeletal muscle mass during HCC treatment in patients with CLD.
INTRODUCTION

P
HYSICAL ACTIVITY HAS preventive effects on cancer, and favorable effects have recently been reported in patients with cancer. 1 Regular physical activity following cancer diagnosis reduces cancer recurrence and mortality in patients with colon cancer 2 and breast cancer. 3 Although physical activity is known to exert significant anticancer effects, 1 most cases of HCC develop in patients with CLD, in which multiple organ dysfunctions are frequently seen. 4 Cardiac function and pulmonary gas exchange are commonly impaired in patients with cirrhosis. 5 Muscle atrophy is also frequently seen in patients with cirrhosis. 6, 7 Patients with cirrhosis cannot sustain the exercise test until achieving their predicted maximal cardiac frequency, indicating an impairment of exercise tolerance. 8 In addition, exercise increases portal pressure 9 and deteriorates the glomerular filtration rate in cirrhotic patients, 10 suggesting that exercise may promote gastrointestinal bleeding and hepatorenal syndrome. Thus, the safety of exercise must first be clarified in CLD patients with HCC.
Physical disability affects quality of life in CLD patients. The 6MWT is an easy and inexpensive method for assessing physical ability by measuring the distance ambulated during the test. 11 Although the 6MWT was originally developed for patients with chronic heart failure, it has been used in patients with pulmonary, neuromuscular, and mental diseases. 12, 13 The 6MWT has also been reported to be useful for patients with cirrhosis. de Lima et al. reported that the 6MWT ambulation distance is associated with nutritional status and cardiovascular complications in patients with cirrhosis. 14 Alameri et al. reported that the 6MWT ambulation distance is a useful tool for assessing the prognosis of patients with cirrhosis. 15 Recently, in addition to the ambulated distance, heart rate variability in the 6MWT has been increasingly used to assess functional autonomic status in patients with various diseases. 16 Accordingly, it is important to maintain or improve physical ability in cirrhosis patients with HCC. However, the effects of therapeutic exercise on the 6MWT remain unclear.
Skeletal muscles play crucial roles in glucose, protein, and ammonia metabolism. 17, 18 Skeletal muscle atrophy is frequently seen in patients with CLD. Skeletal muscle mass is an independent predictor for the development and recurrence of HCC. 19, 20 Skeletal muscle atrophy is also an independent prognostic factor for patients with liver cirrhosis and HCC. [21] [22] [23] Prevention of skeletal muscle atrophy is an important issue for the management of patients with CLD. However, patients with CLD mostly rest in bed during hospitalization for HCC treatment, and we previously reported that skeletal muscle mass is significantly reduced during hospitalization for HCC treatment in patients with cirrhosis. 24 It remains unclear if therapeutic exercise is able to prevent skeletal muscle atrophy during hospitalization for HCC treatment. Moreover, the factors associated with skeletal muscle atrophy remain unknown in patients with CLD.
The aim of this study was to evaluate the effects of therapeutic exercise on liver function, physical ability, and skeletal muscle mass during hospitalization for HCC treatment in patients with CLD. In addition, we investigated factors associated with skeletal muscle atrophy in patients with CLD using data-mining analysis.
METHODS
Study design
T HERAPEUTIC EXERCISE WHILE hospitalized for chemotherapy for cancer is an approved health care service covered by the Ministry of Health, Labour and Welfare of Japan health insurance. Therefore, intentional setting of a control group (no therapeutic exercise group) is contrary to medical ethics. Thus, we carried out a prospective before and after study to evaluate effects of therapeutic exercise on liver function, physical ability, and skeletal muscle mass during hospitalization for HCC treatment in patients with cirrhosis.
Ethics
The study protocol conformed to the ethical guidelines of the Declaration of Helsinki as reflected in the prior approval given by the institutional review board of Kurume University (Kurume, Japan). Informed consent for participation in the study was obtained from each patient. None of the patients were institutionalized.
Subjects
Inclusion criteria were hospitalized CLD patients with HCC who were: (i) 20 years of age or more; (ii) performance status of grade 0 or 1 as defined by the Eastern Cooperative Oncology Group; and (iii) treated with chemotherapy such as TACE, sorafenib, or hepatic arterial infusion chemotherapy. Exclusion criteria were cirrhotic patients with: (i) risk of HCC rupture; (ii) Child-Pugh class C; (iii) hepatic encephalopathy grade 2-4 of the West Haven Criteria; 25 (iv) risk of esophageal varices rupture; (v) heart failure; or (vi) respiratory failure. From February 2013 to May 2015, we enrolled 54 consecutive patients with CLD and HCC.
Definition of liver cirrhosis
Liver cirrhosis was diagnosed by APRI; serum AST level (U/L)/upper limit of normal AST (33 U/L) × 100/platelet count (×10 6 /mL). The APRI is a non-invasive index and can predict liver cirrhosis. Patients with APRI values above 1.0 were diagnosed with liver cirrhosis as previously described. 26 
Definition of BCAA supplementation
Branched-chain amino acid supplementation (BCAA granules and BCAA-enriched nutrients) is an approved medication for liver cirrhosis in Japan. According to the indication criteria, BCAA (5.5-12.0 g/day) was given to cirrhotic patients with hypoalbuminemia or hepatic encephalopathy (BCAA granules, n = 28; BCAA-enriched nutrients, n = 4).
Diagnosis, TNM staging, and treatment of HCC Hepatocellular carcinoma was diagnosed by a tumor biopsy or a combination of tests for serum tumor makers such as α-fetoprotein and des-γ-carboxy prothrombin, and imaging procedures such as ultrasonography, computed tomography, magnetic resonance imaging, and/or angiography. The clinical stage of HCC was evaluated by TNM staging based on the Liver Cancer Study Group of Japan criteria. 27 According to this criteria, the T-factor was defined as (1) single, (2) <2 cm, or (3) no vascular involvement, and the stage was defined as follows: stage I, T1 (fulfilling three T-factors), N0, M0; stage II, T2 (fulfilling two T-factors), N0, M0; stage III, T3 (fulfilling one Tfactor), N0, M0; stage IV-A T4 (fulfilling 0 T-factors), N0, M0; and stage IV-B (fulfilling any number of T-factors), N0-1, M1. 27 The treatment for HCC was selected based on the evidence-based clinical practice guidelines for HCC of The Japan Society of Hepatology. 28 
Therapeutic exercise regimen
To maintain physical ability and prevent disuse muscle atrophy during hospitalization for HCC treatment, enrolled patients were treated with 2.5-4.0 MET/20 min/time ( Fig. 1 ) of therapeutic exercise instructed by physical therapists certified in the rehabilitation of cancer patients. The therapeutic exercise consisted of the following four types of training according to the guidelines of American College of Sports Medicine. 29 The therapeutic exercise was initiated on the next day of the HCC treatment unless the patients had a fever over 38°C.
Stretching
At the beginning of therapeutic exercise, patients undertook a series of stretches for 3 min, targeting the quadriceps femoris muscles, hamstrings, hip adductor muscles, and gastrocnemius. A static stretch was held for 10-20 s at the point of feeling tightness or slight discomfort. 
Strength training
After finishing the stretching, patients underwent strength training for 5 min, targeting the bilateral quadriceps femoris muscles, iliopsoas, gastrocnemius, and tibialis anterior muscle. Bilateral quadriceps femoris muscle and iliopsoas strength training were performed at 60-70% of one repetition maximum (moderate to hard intensity) using a weight band. Bilateral gastrocnemius and tibialis anterior muscles were strength trained used the patient's weight. One set consisted of 8-12 repetitions, and a maximum of three sets were performed. 29 
Balance practice
After finishing the strength training, patients practiced a tandem stand, the toes of the back foot touch the heel of the front foot at each step, or one-leg standing for 4 min. 29 
Endurance training
After balance practice, the patients were trained with bicycle ergometers or walking for 8 min. The intensity of exercise was adjusted by 11-13 points on the Borg scale, a subjective rating of perceived exertion, and the target heart rate was adjusted by the Karvonen Formula. 29 
Safety evaluation
Safety of the therapeutic exercise was evaluated by the following measurements:
Incidence of bone fracture and postponement or cancellation of HCC treatment During admission, the incidence of bone fractures and postponement or cancellation of HCC treatment due to any exercise-related adverse events was evaluated by certified nurses, certified physical therapists, or medical doctors.
Muscle injury and renal function
Effects of the therapeutic exercise on muscle injury and renal function were evaluated by changes in biochemical tests from admission to discharge. To evaluate muscle damage, serum levels of AST, lactate dehydrogenase, and creatine kinase were measured using standard clinical methods (Department of Clinical Laboratory, Kurume University Hospital). To evaluate renal function, serum levels of BUN, creatinine, sodium, potassium, and chloride were measured, and eGFR was calculated.
Primary outcome measurements
Primary outcomes were changes from admission to discharge in liver function including Child-Pugh class, 6MWT, and skeletal muscle mass.
Liver function
The liver function tests measured were serum levels of ALT, ALP, GGT, total bilirubin, albumin, prothrombin activity, total cholesterol, and triglycerides. We also evaluated changes between admission and discharge in Child-Pugh class. 30 
Six-minute walking test
The 6MWT was carried out according to the American Thoracic Society guidelines and supervised by qualified physical therapists. 31 Briefly, patients were instructed to walk at their usual pace for 6 min and then to be seated for a 1-min recovery period. Oxygen saturation, heart rate, and Borg scale (based on an exertion scale: 6, no exertion; 9, very light; 13, somewhat hard; 17, very hard; and 20, maximal exertion) were measured at the beginning and the end of the 6MWT and 1 min after completion of the walking test. Ambulated distance was defined as the total distance walked during the 6MWT. 31 Physical function was assessed by changes in the Borg scale between the end of the 6MWT and 1 min after completion of the walking test (Borg scale). In addition, physical function was evaluated by the AUC for heart rate variability (arbitrary units) during the 6MWT and 1 min after completion of the walking test.
Skeletal muscle mass
Body composition, including skeletal muscle mass, was measured by a bioelectrical impedance analyzer (InBody720; BioSpace, Tokyo, Japan). The BIA measurement was carried out under the following conditions according to recommendations for the clinical application of BIA: (i) fasting for 4 h before measurement; (ii) bladder voided before measurement; and (iii) no exercise in the 8 h prior to measurement. 32 The BIA used in this study was an eight-polar direct segmental multifrequency BIA able to evaluate not only total muscle mass, but also the muscle mass of the right arm, left arm, trunk, right leg, and left leg using the software supplied with the BIA (Lookin'body; BioSpace). The BIA also measured the total fat mass and edema index, which were evaluated by the extracellular water to total body water ratio. Muscle atrophy was defined as 7.0 kg/m 2 for men and 5.7 kg/m 2 for women according to the definition of the Asian Working Group for Sarcopenia.
Secondary outcome measurements
Secondary outcomes were changes from admission to discharge in symptoms, ADL, anthropometry, muscle strength, and static balance.
Symptoms
Fatigue was evaluated by the CFS developed by the National Cancer Center Research Institute East of Japan. 34 The CFS consists of a 15-item scale composed of three subscales (physical, affective, and cognitive subscales). 34 In addition, physical symptoms (muscle cramps, constipation, and pain) and mental symptoms (appetite, insomnia, and anxiety) were evaluated by the visual analog scale (1, none; 10, severe). 35 Activity of daily living, muscle strength, and static balance Activity of daily living was evaluated by the performance status defined by the Eastern Cooperative Oncology Group translated by the Japan Clinical Oncology Group, 36 ranging from 0 (fully active) to 5 (dead). Activity of daily living was also evaluated by the Barthel index. 37 The Barthel index evaluates 10 items including feeding, grooming, dressing, bathing, toileting, bladder and bowel continence, ambulation, transfers, mobility, and stairs. All the activities were scored, and the total score reflected the patient's level of independence ranging from 0 (totally dependent) to 100 (completely independent). 37 The performance status and Barthel index were evaluated by certified physical therapists.
Muscle strength was evaluated by handgrip and MMT. Hand grip strength was measured bilaterally using a dynamometer (TKK5401; Takei Scientific Instruments Co., Ltd., Niigata, Japan). The MMT was scored by the six-point Medical Research Council scale. Strength was evaluated bilaterally for hip flexion, knee extension, knee flexion, ankle dorsiflexion, and ankle plantarflexion. 38 Balance was evaluated by the one-leg standing time. One-leg standing time with eyes open was measured on both sides. The time until the raised leg was set down on the floor was measured, with a maximum time of 60 s recorded for those who could stand on one leg for more than 60 s. 39 
Anthropometry
The circumference of the thigh, patella, and calf was measured with a pull tape measure by certified physical therapists. 40 The thigh was measured at 10 cm above the upper end of the patella. The patella was measured at the upper end of the patella. The calf was measured at the maximum circumference of the calf. 41 
Statistical analysis
Data are expressed as the median (IQR), range, or number. Differences between measurements on admission versus on discharge were analyzed by using Wilcoxon signed rank tests. The level of statistical significance was set at P < 0.05. In addition, independent factors associated with changes in skeletal muscle atrophy were analyzed by using a decision-tree analysis as described previously. 42 
RESULTS
Patient characteristics
T HE PATIENT CHARACTERISTICS are summarized in Table 1 . The median age was 76 years, and the ratio of women to men was 1:1.25 (24/30 33 was seen in 11.1% (6/54) of enrolled patients and all of the sarcopenic patients were ≥75 years old.
Implementation status of therapeutic exercise
The median period of hospitalization was 13 days (IQR, 8-19 days; range, 4-52 days). During hospitalization, the median length of therapeutic exercise was 7.5 days (IQR, 5-10 days; range, 3-26 days). The median total time of therapeutic exercise was 210 min (IQR, 175-285 min; range, 80-520 min) ( Table S1 ).
Safety of therapeutic exercise
During the hospitalization, no patients had bone fractures. There was no postponement or cancellation of HCC treatment due to any exercise-related adverse events. On discharge, no significant increase was seen in serum levels of AST, lactate dehydrogenase, or creatine kinase compared to those on admission (Table 2 ). Serum levels of BUN, creatinine, sodium, potassium, chloride, and eGFR on admission did not significantly increase compared to those on admission (Table 2) .
Primary outcomes
Liver function tests S ERUM LEVELS OF ALT, ALP, GGT, and total bilirubin on discharge did not significantly increase compared to those on admission (Table 3) . On the contrary, serum levels of ALT, GGT, and total bilirubin on discharge were significantly decreased compared to those on admission (Table 3) . Serum levels of albumin, prothrombin activity, total cholesterol, and triglycerides on discharge did not significantly decrease compared to those on admission. There were no significant changes in the distribution of Child-Pugh class between admission and discharge (Table 3) .
Six-minute walk test
There was no significant difference in the distance ambulated during the 6MWT between admission and discharge (Fig. 2a) . At the end of 6 min of walking, no significant difference was seen in oxygen saturation, heart rate, or Borg scale between admission and discharge ( Fig. 2b-d) . We also evaluated changes in the Borg scale between completion of the 6MWT and 1 min after completion of the walking test (Borg scale = Borg scale at 1 min after completion of 6MWT -Borg scale at 6 min). The Borg scale was significantly decreased on discharge compared to that on admission (Fig. 2e) . Moreover, heart rate variability was evaluated by measuring an AUC during the 6MWT and 1 min after completion of the walking test. The AUC for heart rate variability on discharge was significantly decreased compared to that on admission (Fig. 2f) . 
Skeletal muscle mass
Body weight on discharge was significantly decreased compared to that on admission (Table 4) . Although no significant decrease was seen in body fat mass on discharge, skeletal muscle mass on discharge was significantly decreased compared to that on admission (Table 4) . Segmental skeletal muscle mass was evaluated in five areas, and except for skeletal muscle mass of the right arm, four areas of segmental skeletal muscle mass (left arm, trunk, right leg, and left leg) were significantly decreased on discharge compared to that on admission (Table 4) . In order to clarify the clinical profile of the reduction in skeletal muscle mass, a decision-tree algorithm was created using two divergence variables to classify three groups of patients (Fig. 3) . Median reduction of skeletal muscle mass was À0.6 kg in all patients. Supplementation with BCAA was identified as the first divergence variable. In patients with no BCAA supplementation, skeletal muscle mass was reduced À1.1 kg. However, in patients treated with BCAA supplementation, reduction of skeletal muscle mass was À0.5 kg (Fig. 3) . Among the patients treated with BCAA supplementation, age was the variable for the second division. In patients treated BCAA supplementation who were <75 years old, reduction of skeletal muscle mass was À1.1 kg. However, in patients treated with BCAA supplementation who were ≥75 years old, reduction of skeletal muscle mass was À0.3 kg (Fig. 3) .
Secondary outcomes
Symptoms F ATIGUE WAS EVALUATED by CFS. On discharge, the total fatigue score was not increased compared to that on admission (Table S2) . Physical, affective, and cognitive aspects of fatigue are three subscales of CFS. There was no significant increase in any of these three subscale scores on discharge compared to admission (Table S2) . Symptoms other than fatigue were evaluated by the visual analog scale. There was no significant worsening in loss of appetite, sleepless, constipation, pain, or anxiety between admission and discharge. Moreover, muscle cramp on discharge was significantly improved compared to that on admission (Table S3 ). In
Activity of daily living, muscle strength, and static balance
Performance status and Barthel index were maintained on discharge compared to those on admission (Table 4) . Bilateral handgrip strength was also maintained on discharge compared to that on admission (Table 4) . Similarly, the MMT scores for bilateral hip flexion, knee flexion, knee extension, ankle dorsiflexion, and ankle plantarflexion were maintained on discharge compared to those on admission (Table 4 ). In addition, bilateral one-leg standing times were maintained on discharge compared to those on admission (Table 4) .
Anthropometry
The circumference of the thigh, patella, and calf was also maintained on discharge compared to that on admission (Table S4) .
DISCUSSION
I N THIS STUDY, we showed that therapeutic exercise significantly improved physical ability without worsening liver function during hospitalization for HCC treatment in patients with CLD. Exercise could not fully prevent reduction of skeletal muscle mass; however, ADL, muscle strength, static balance, and anthropometry were preserved. In addition, decision-tree analysis revealed that BCAA treatment was the most distinguishable factor for minimizing muscle mass atrophy. Thus, exercise with BCAA supplementation may be important for the management of CLD patients with HCC.
To maintain physical ability and prevent disuse muscle atrophy, patients with CLD undertook a combination of stretching, strength training, balance practice, and endurance training (2.5-4 MET/20 min/day). This therapeutic exercise did not worsen liver or renal functions. In contrast, Salo et al. reported that moderate physical exercise impairs renal function in patients with cirrhosis, 10 suggesting that exercise has a potential risk of hepatorenal syndrome. Although the discrepancy between the previous findings and our findings remains unclear, possible explanations could be: (i) most of the subjects in the previous study had Child-Pugh class C cirrhosis, whereas patients with Child-Pugh class C cirrhosis were excluded from our study; and (ii) 30 min of moderate cycloergometric exercise was carried out in the previous study, whereas only 8 min of cycloergometric exercise was carried out in our study. In addition, the exercise intensity was adjusted from light to somewhat hard on the Borg scale according to the physical ability of each patient in our study. Our findings are in good accordance with a previous study by Zenith et al., in which no relevant adverse effects were observed during 8-10 min of cycloergometric exercise at 50% of the peak workload in patients with Child-Pugh class A or B cirrhosis. 43 Moreover, effects of the therapeutic exercise on liver function tests may be masked by the treatment of HCC, including TACE, which could worsen liver function tests. Thus, our exercise program may be safely undertaken, even in patients with liver cirrhosis. Although the development of a therapeutic exercise program for patients with CLD is an important issue, so far there has been no consensus on what program to use. Our therapeutic exercise program consisted of four types of training and was completed safely without worsening liver function; it may be a suitable exercise program for patients with Child-Pugh class A or B cirrhosis.
The 6MWT is an easy and inexpensive assessment method for physical ability by measuring ambulated distance, recovery of heart rate, and Borg scale after 6 min of walking. In this study, we showed that the 6MWT ambulation distance was maintained during hospitalization. Moreover, on discharge, recovery according to the Borg scale 1 min after the 6MWT was significantly improved compared to that on admission. Furthermore, heart rate variability during the 6MWT and 1 min after completion of the 6MWT was significantly decreased compared to that on admission, suggesting an improvement in physical ability. Physical ability is regulated by various factors including muscle strength and fatigue. 15 However, these factors did not significantly change in this study, indicating that therapeutic exercise increases physical ability through amelioration of cardiopulmonary function in CLD patients with HCC. The ambulated distance of the 6MWT is reported to be associated with nutritional status 14 and mortality 15 in patients with cirrhosis. Moreover, heart rate variability during the 6MWT is reported to be a powerful prognostic indicator in patients with heart failure. 44 Thus, our data, along with previous findings, suggest that therapeutic exercise may have beneficial effects on not only physical ability, but also survival in CLD patients with HCC.
We previously showed that the skeletal muscle mass was significantly reduced during hospitalization for HCC treatment. 24 Although skeletal muscle atrophy was not fully prevented in this interventional study, we compared the data between this study and our previous observational study. 24 There was no significant difference in age, sex, Although this is a historical control, these data may indicate that the in-hospital therapeutic exercise suppresses the muscle atrophy in HCC patients with CLD. In addition, muscle strength was maintained during hospitalization in our study. Lixandrão recently reported that muscle hypertrophy is observed after 9 weeks of resistance training in the elderly. 45 In this study, the median age of the participants was 76 years, and the median exercise term was 13 days, indicating that our protocol was too short to evaluate skeletal muscle mass. Thus, our therapeutic exercise may be useful for maintaining muscle strength in CLD patients with HCC. Moreover, these data also indicate that other therapeutic strategies are required in addition to exercise to prevent skeletal muscle atrophy.
Skeletal muscle atrophy can be caused by various factors including malnutrition. 46 In this study, a data-mining analysis revealed that BCAA supplementation was the most distinguishable factor for minimizing the loss of skeletal muscle mass in CLD patients with HCC. Patients with cirrhosis frequently have malnutrition featuring a depletion of serum BCAA. 47 Although it is unclear why BCAA supplementation was associated with minimization of the loss of skeletal muscle mass in this study, BCAA, in particular leucine, increases protein synthesis through activation of the mammalian target of rapamycin signaling pathway in the skeletal muscles. 47 Leucine is metabolized to α-ketoisocaproate and β-hydroxy-β-methylbutyrate in the skeletal muscles, which inhibit protein degradation. 48 Recently, Bukhari et al. reported that leucine-rich amino acid supplementation stimulates muscle anabolism in elderly women. 49 Moreover, Tsien et al. reported that BCAA reverses increased autophagy in the skeletal muscles of patients with alcoholic cirrhosis. 50 Taken together, along with therapeutic exercise, BCAA supplementation seems to be beneficial for alleviation of skeletal muscle atrophy during hospitalization for HCC treatment in patients with CLD.
"More than 75 years old" was the second distinguishable factor for minimizing the loss of skeletal muscle mass in CLD patients with HCC treated with BCAA supplementation. It is still unclear the reason why skeletal muscle atrophy was significantly minimized in CLD patients ≥75 years old than in CLD patients <75 years old. However, skeletal muscle mass in CLD patients aged 75 years or older was significantly lower than that in CLD patients younger than 75 years. Therefore, possible explanations might be that there was not enough skeletal muscle mass to reduce, or that skeletal muscle mass tended to increase in CLD patients aged ≥75 years compared to CLD patients aged <75 years.
A limitation of this study is that this was not a randomized controlled study. However, therapeutic exercise during hospitalization for cancer treatment is an approved health care service by the Ministry of Health, Labour and Welfare of Japan health insurance. Intentional setting of a control group is contrary to medical ethics. Thus, further study will be focused on differences of type, duration, and intensity of therapeutic exercise on liver and physical functions in CLD patients with HCC.
In conclusion, we found that exercise significantly improved physical ability without worsening liver function during hospitalization for HCC treatment in patients with CLD. Although exercise could not fully prevent skeletal muscle atrophy, muscle strength was preserved. We also found that BCAA treatment minimized skeletal muscle atrophy. Thus, exercise with BCAA treatment may be important in the management of CLD patients with HCC.
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